Table 2.
Summary of prophylactic protocol involving HBIG use at different transplant programs
| References | Regimen |
|---|---|
| Uemoto [18] | HBIG 100 IU/Kg IV during anhepatic phase and then daily × 7 days, followed by 1,000 IU booster to maintain anti-HBs >100 IU/L |
| Dodson [34] | HBIG 10,000 IU IV during anhepatic phase and then daily × 7 days, followed by HBIG 10,000 IU IV monthly × 6 months, then HBIG 1,000 IU IM every 2 weeks × 18 months plus LAM 150 mg daily lifelong |
| Loss [35] | HBIG 10,000 IU IV during anhepatic phase plus LAM 150 mg daily lifelong* |
| Manzarbeitia [21] | HBIG 10,000 IU IV monthly × 6 months to maintain anti-HBs >100 IU/L |
| Roque-Afonso [20] | HBIG 5,000 IU IV daily × 7 days, followed by booster to maintain anti-HBs >100 IU/L |
| Holt [36] | HBIG 10,000 IU IV daily × 7 days plus LAM 150 mg b.i.d. × 2 years |
| Chang [37] | HBIG 100 IU/Kg IV intraoperatively and then daily × 3 days, followed by booster to maintain anti-HBs >20 IU/L plus vaccination based on anti-HBs titer |
| Fabrega [38] | HBIG 10,000 IU IV during anhepatic phase and then daily × 7 days plus LAM 100 mg daily¥ |
| Nery [29] | HBIG 10,000 IU IV intraoperatively and then daily × 7 days, weekly × 1 month, and monthly × 6 months and/or LAM 150 mg daily lifelong¶ |
| Lee [15] | HBIG (100 IU/Kg for children and 10,000 IU for adults) IV daily × 7 days, followed by booster to maintain anti-HBs > 200 IU/L |
| Suehiro [39] | HBIG 10,000 IU IV during anhepatic phase and then 2,000 IU IV daily × 7 days, followed by 2,000 IU IV every 2 months to maintain anti-HBs > 100 IU/L plus LAM 100 mg daily |
| Donataccio [24] | HBIG 10,000 IU IV during anhepatic phase and then daily × 7–10 days to maintain anti-HBs >250 IU/L† |
| Kwon [40] | HBIG 4,000 IU IV during anhepatic phase and then daily × 3 days |
| Umeda [41] | HBIG 200 IU/Kg IV during anhepatic phase and then daily × 7 days, followed by 1,000 IU periodically to maintain anti-HBs > 200 IU/L |
| Yen [42] | HBIG 10,000 IU IV during anhepatic phase and then daily × 7 days plus LAM 100 mg daily lifelong |
| Takemura [33] | HBIG 10,000 IU during anhepatic phase, then once a month to keep anti-HBs >200 IU/L during first year and 100 IU/L thereafter |
| Park [43] | HBIG 100 IU/Kg IV during anhepatic phase and then daily × 7 days, followed by booster 100 IU/kg IV to maintain anti-HBs >200 IU/L × 1 year. Vaccination to maintain anti-HBs >200 IU/L after 1 year |
| Pan [26] | HBIG variable dose IV perioperatively unless recipient is already anti-HBs positive plus LAM 100 mg daily lifelong |
| Roche [27] | HBIG 5,000 IU IV perioperatively, followed by booster to maintain anti-HBs >100 IU/L |
HBIG hepatitis B immune globulin, LAM lamivudine, IU international unit, IV intravenous, IM intramuscular, anti-HBs antibody against hepatitis B surface antigen, b.i.d. twice a day
* Prophylaxis was administered based on the presence or absence of HBV DNA in donor’s serum and/or liver
¥Prophylaxis was discontinued if there was no HBV DNA detected in donor’s serum and liver
¶Prophylaxis use was based on the presence or absence of donor and recipient risk factors for de novo hepatitis B
†Prolongation of prophylaxis was based on the results of immunohistochemistry of day 0 and day 7 liver biopsies after transplantation